Evidence map›Paper›PMID 37056132›Full record

ArticleNeural regeneration research2023

Disease-associated oligodendrocyte signatures in neurodegenerative disease: the known and unknown.

Kristen H Schuster, Hayley S McLoughlin

Abstract read
In one paragraph

Article in Neural regeneration research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kristen H SchusterDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.
Hayley S McLoughlinDepartment of Neurology, University of Michigan, Ann Arbor, MI, USA.

Funding

Nonneuronal Mechanisms of Polyglutamine NeurodegenerationR01NS122751 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCLOUGHLIN, HAYLEY S · 2021 to 2025
$2.2M
Preclinical Development of Antisense Oligonucleotide Therapy for Spinocerebellar Ataxia Type 3U01NS106670 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCLOUGHLIN, HAYLEY SARAH, PAULSON, HENRY L · 2018 to 2021
$2.1M
Defining Biomarkers for Spinocerebellar Ataxia Type 3R21NS111154 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCLOUGHLIN, HAYLEY SARAH, OZ, GULIN · 2019 to 2019
$435k
NINDS NIH HHS R01 NS122751NINDS NIH HHS R21 NS111154NINDS NIH HHS U01 NS106670
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37056132
PMCPMC10328287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.